Medicofarma Biotech (WAR:MDB) ROCE %: -23.55% (As of Mar. 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
28 GF Score
Price zł0.45
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech ROCE %?

Medicofarma Biotech WAR:MDB 28 ROCE % is -23.55% as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 28/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medicofarma Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was -23.55%.

Medicofarma Biotech  (WAR:MDB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medicofarma Biotech ROCE % Related Terms

Medicofarma Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech ROCE % Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.89 -11.81 -30.03 -20.30 -16.23

Medicofarma Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.92 -28.16 -33.11 21.73 -23.55
WAR:MDB
28GF Score
Medicofarma Biotech SA WAR:MDB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech ROCE % Calculation

Medicofarma Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-1.611/( ( (14.71 - 4.775) + (14.203 - 4.284) )/ 2 )
=-1.611/( (9.935+9.919)/ 2 )
=-1.611/9.927
=-16.23 %

Medicofarma Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-2.292/( ( (14.203 - 4.284) + (13.835 - 4.287) )/ 2 )
=-2.292/( ( 9.919 + 9.548 )/ 2 )
=-2.292/9.7335
=-23.55 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -23.55% mean?
Medicofarma Biotech (WAR:MDB) has a ROCE % of -23.55% as of Mar. 2026.
Is Medicofarma Biotech's ROCE % too high?
Medicofarma Biotech's current ROCE % is -23.55%. Overall, Medicofarma Biotech has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's ROCE % compare to ZTS and UTHR?
Medicofarma Biotech's ROCE % of -23.55% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current ROCE % is -23.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.45 — trading 792% above its estimated fair value. The current ROCE % is -23.55%. Medicofarma Biotech's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current ROCE % is -23.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.45 is trading 792% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • ROCE %: -23.55%
  • GF Value™: zł0.05 vs. price of zł0.45 (792% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
28GF Score

Get the complete analysis for WAR:MDB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.45
Price
zł0.05
GF Value